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Abstract 
Attention deficit hyperactivity disorder (ADHD) is a complex psychiatric disorder, 
commonly of childhood onset, with profound implications when ineffectively treated.  
The core symptoms of inattention, hyperactivity, and impulsivity have implications on 
social interactions, educational performance, relationships, and emotional stability  
(National Institute of Mental Health, 2017). There is a growing interest for the use of 
non-stimulant medications due to the concern over stimulants abuse potential and other 
adverse effects.  The purpose of this literature review was to increase the knowledge of 
Advanced Practice Psychiatric Nurses (APPNs) on the effectiveness of non-stimulants for 
the treatment of ADHD in the pediatric population.  More specifically, the research on 
the non-stimulants atomoxetine, clonidine extended-release (ER) and guanfacine ER will 
be analyzed.   APPNs have the obligation under their the scope of practice to stay current 
on evidence-based practice, promote research, and provide holistic care to the psychiatric 
mental health population (American Nurses Association, 2014).  By increasing their 
knowledge, APPNs will further their ability to provide safe and effective care to the 
pediatric population with ADHD. Furthermore, this knowledge can be used to share with 
patients and their families during collaborative treatment planning. This paper was 
designed to review current research articles from 2007 to present on three ADHD specific 
non-stimulant medications. A review of literature was performed using Harley E. French 
Library of the Health Sciences utilizing the search engines of CINAHL, PubMed, and 
PsycInfo.  The literature reviewed found statistically significant results supporting these 
non-stimulants as effective medications for children and adolescents with ADHD.  
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The Effectiveness of Non-Stimulants for the Treatment of Attention Deficit Hyperactivity 
Disorder in the Pediatric Population 
 Attention deficit hyperactivity disorder (ADHD) is defined as a 
neurobehavioral/neurodevelopmental disorder primarily of childhood onset.  Inattention, 
hyperactivity, and impulsivity are labeled as core symptoms of ADHD, which are also 
the main symptoms that are targeted by psychotropic medications (National Institute of 
Mental Health, 2017).  However, targeting these core symptoms with medications has 
been difficult.  The common use of stimulants has been under scrutiny by 
parents/guardians, media, and health care professionals due to their abuse potential and 
other adverse effects like appetite suppression and insomnia (Lakhan & Kirchgessner, 
2012).  Therefore, there is a demand to find medications that are safe and effective. Thus, 
the growing interest for non-stimulants has emerged to treat ADHD.  
 According to the American Psychiatric Association (2013), 5% of children have 
ADHD. There is new criteria for ADHD in the Diagnostic and Statistical Manual of 
Mental Disorders Fifth Edition (DSM-V), thus it is estimated that the prevalence may be 
closer to 8-12% (Botero-Franco, Palacio-Ortiz, Arroyave-Sierra, & Pineros-Ortiz, 2016). 
With the increase in the number of children being diagnosed with ADHD, the number of 
children being treated with medications is also increasing.  Among adolescents, it is the 
most prevailing behavioral disorder and most common reason to seek treatment for 
behavioral concerns (Hogue, Bobek, Tau, & Levin, 2014).  It is estimated that there has 
been a 28% increase in the pharmacological treatment of ADHD in children from 2007 to 
2012 (Centers for Disease Control and Prevention, 2017).   With the increasing diagnoses 
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of ADHD, use of medications, and concern over stimulants, the use of non-stimulants is 
also increasing in the pediatric population.   
 Without proper treatment, ADHD can have a profound effect on a child’s 
development.  Children with ADHD are affected in their social functioning, education, 
interpersonal relations, emotional stability, and family relations (National Institute of 
Mental Health, 2017).  When there is no treatment or treatment is ineffective at treating 
the core symptoms, children have great difficulty thriving in school, socializing with 
others, coping with their symptoms, and are at increased risk for substance abuse and 
other co-morbid learning and behavioral disorders (Shier, Reichenbacher, Ghuman, & 
Ghuman, 2013).  There is also growing concern over the use of stimulants and growing 
trend in the use of non-stimulants.  Therefore, Advanced Practice Psychiatric Nurses 
(APPNs) should be knowledgeable in how to safely and effectively treat ADHD in 
children. This literature review will provide insight into the effectiveness of non-
stimulants in the treatment of ADHD in the pediatric population.  The focus of the 
literature review will be on the ADHD-specific non-stimulants atomoxetine (Strattera), 
clonidine ER (Kapvay), and guanfacine ER (Intuniv).    
 Purpose 
The purpose of this literature review is to provide APPNs with current evidence-
based knowledge on the effectiveness of non-stimulants to guide their prescribing 
decisions for the treatment of ADHD in the pediatric population.  According to the 
American Nurses Association (2014), education is the 8th Standard of Practice under their 
scope and standards practice for which the APPN utilizes evidence-based research 
findings to enhance clinical knowledge.   This literature review will also adhere to  
  
EFFECTIVENESS OF NON-STIMULANTS FOR ADHD                                             5      
Standard 10, Quality of Practice, by enhancing the APPN’s knowledge to improve their 
quality of care, improve their prescriptive decision-making process and therefore enhance 
the outcome/effectiveness of the treatment of ADHD in the pediatric population.  
Furthermore, Standard 5D Prescriptive Authority and Treatment, states for the APPN to 
be knowledgeable in medication’s efficacy, side effects, mechanism of actions, and the 
consumers individualized needs when using their prescriptive authority (American 
Nurses Association, 2014).     
This paper provides education to the APPN on the effectiveness of atomoxetine 
(Strattera), clonidine ER (Kapvay), and guanfacine ER (Intuniv) so the APPN can use 
this knowledge when choosing treatment plans for children with ADHD while following 
the Scope and Standards of Practice by the American Nurses Association. This paper will 
define key terms, review and summarize current evidence-based research findings, 
describe search methods that were utilized for the research, and discuss the implications 
of these findings in regards to the APPN’s role in practice, research, education, and 
health policy.  With the growing percentage of children being diagnosed and being 
treated for ADHD, this knowledge is prudent to improving the quality of care the APPN 
delivers to this young population.   
Significance 
Effectively treating ADHD in the pediatric population does not come easy due to 
concerns regarding safety and tolerability of ADHD medications.  Using stimulants to 
treat ADHD in children has been well researched and proven to be highly effective, 
however, these medications have an abuse potential and may cause undesirable side 
effects that cause clinicians and parents to prefer not to use these medications and look to 
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other medications that can be effectively used (Martinez-Raga, Ferreros, Knecht, De 
Alvaro, & Carabal, 2017).  The desire for clinical guidelines for ADHD in pediatrics has 
not been overseen.  The American Academy of Child and Adolescent Psychiatry (2017) 
is creating its first clinical practice guidelines for treating ADHD due to this demand.  
Furthermore, the American Academy of Pediatrics has a strong recommendation for 
children and adolescents to be treating with Food and Drug Association (FDA) approved 
ADHD medications (American Academy of Family Physicians, 2017).  With the well-
known and highly publicized knowledge of stimulants holding an abuse potential, the 
education of non-stimulants that are FDA approved for ADHD which do not have an 
abuse potential should also be publicized regarding their effectiveness.  Since non-
stimulants are gaining popularity to treat ADHD in the pediatric population, the APPN 
needs to be knowledge regarding the their effectiveness to treat ADHD in this population.   
It is highly important to know how to effectively treat ADHD with the pediatric 
patient because ADHD can have negative outcomes that sustain throughout childhood 
and extend into adulthood.  Children with ADHD have poorer academic performance 
which leads to an increased risk for failing or dropping out.  There is also an increase in 
relationship problems with other children and family members (Riera, Castells, Tobias, 
Cunill, Blanco, & Capella, 2017). Adolescents with ADHD were found to have a poorer 
working memory as evident on magnetic resonance imaging in the caudate region, 
furthermore, abnormalities were found in the limbic, frontal, and striatal areas (Roman-
Urrestarazu et al., 2016). Young adults with ADHD are more likely to have legal and 
substance abuse problems, and are more prone to injuries (Kovshoff, Williams, Vrijens, 
Danckaerts, Thompson, Yardley, & Sonuga-Barke, 2012).  Overall, the toll on children 
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with ADHD can be exhibited on their mental health, academics, social functioning, and 
interpersonal relationships, which leaves them at increased risk for other comorbid 
mental health disorders when left untreated or ineffectively treated (National Institute of 
Mental Health, 2017).  
The APPN’s knowledge of non-stimulant effectiveness will be a valuable tool to 
utilize as more and more patients and families are seeking out health care providers that 
are specialized in psychiatry.  Children with ADHD are considered a vulnerable 
population due to their young age and mental health diagnoses thus treatment 
management is best to fall under a specialized experienced clinician in this field to yield 
the best patient outcomes (Kovshoff, Williams, Vrijens, Danckaerts, Thompson, Yardley, 
& Sonuga-Barke, 2012).  Due to the DSM-V changing its age criteria for symptoms to 
present prior to age 12 verses age 7 in the DSM-IV, it is anticipated that diagnoses will 
increase thus will the increase in demand for APPN’s and their prescribing knowledge 
and authority to treatment these children (American Psychiatric Association, 2013).  
Without a doubt, having the knowledge of non-stimulant effectiveness will positively 
increase the safe and effective quality-of-care the APPN can provide the pediatric ADHD 
population.   
Theoretical Framework 
Understanding the pathophysiology of ADHD can help provide a neurobiological 
framework to utilize in effectively treating ADHD pharmacologically.  In order to know 
if a medication is effective at treating a disease, one must understand the pathophysiology 
of the disease itself. A prescriber then can choose a medication that has a mechanism of 
action that targets the pathophysiology of the disease.  When analyzing if a medication is 
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effective for a treating a disease, it should target the pathophysiology of the disease itself 
and result in positive clinical outcomes of improving symptomology.  Under this 
framework, children and adolescents with ADHD will have improved outcomes because 
the non-stimulant medications are working to target the pathophysiology of the ADHD.   
According to Stahl (2013), “in ADHD, imbalances in NE [norepinephrine] and 
DA [dopamine] circuits in the prefrontal cortex hypothetically causes inefficient 
information processing in prefrontal circuits, and thus the symptoms of ADHD” (p. 475). 
More specifically, the neurotransmitters dopamine (DA) and norepinephrine (NE) are 
decreased in the prefrontal cortical area of the brain, which results in decreased 
stimulation of their receptors.  However, symptomology of ADHD not only results from 
a decrease in these neurotransmitters but also can results from an excessive amount, 
therefore, there needs to be a moderate level of both DA and NE for proper prefrontal 
cortex functioning thus improving the symptoms of ADHD.  Overall, there should be a 
moderate amount of DA to their D1 receptors and moderate amount of NE to their α2A 
receptors (Banaschewski et al., 2005).  In fact,  “properly tuned D1 receptor stimulation 
will reduce noise while α2A receptor stimulation will increase the signal, resulting in 
appropriate prefrontal cortex functioning, guided attention, focus on a specific task, and 
control of emotions and impulses” (Stahl, 2013, p. 483).   
Atomoxetine is known as a norepinephrine transporter (NET) inhibitor, which 
selectively inhibits NE reuptake in the prefrontal cortex.  This reuptake inhibition causes 
an increase in NE and therefore an increase in DA since NETs can also transport DA.  By 
targeting NETs, which are plentiful in the prefrontal cortex, atomoxetine can target 
symptoms of ADHD.   Furthermore, this increase in NE and DA occurs through tonic 
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signaling by downregulation of any phasic actions of NE and DA resulting in the desired 
moderate tonic controlled release.  There is also no abuse potential with atomoxetine 
because there are few NE neurons with NETs in the nucleus accumbens, which is known 
as the reward/abuse center of the brain, additionally, there is no phasic firing which 
occurs with immediate release stimulants (Stahl, 2013).   
 Another way to target NE in the prefrontal cortex is by using an α2 receptor 
agonist such as clonidine.  α2A receptors are highly concentrated in the prefrontal cortex 
thus agonizing α2A receptors causes an increase NE here, which then targets ADHD 
symptoms.  Even though clonidine is an α2 receptor agonist, it is not selective to the α2A 
receptor. Clonidine also has actions on imidoazoline, α2B, and α2C receptors, which can 
be blamed for clonidine’s side effects, but also why clonidine can also have other 
therapeutic effects not specific to the ADHD symptomology (Stahl, 2013).  The 
extended-release (ER) form of clonidine known as Kapvay, allows of tonic (controlled 
release) of NE throughout the day.   
Similar to clonidine, guanfacine is also an α2 receptor agonist.  However, 
guanfacine is highly selective to the α2A receptor, approximately 15-60 times more 
selective than clonidine (Stahl, 2013).  Therefore, guanfacine is more potent to the α2A 
receptors in the prefrontal cortex in targeting the core symptoms of ADHD that are 
manifested in this area of the brain.   
Understanding the role of the DA and NE and their receptors in ADHD is 
essential to guide the APPN’s prescribing decision-making.  Therefore, it is imperative 
that the APPN is also knowledgeable on the mechanism of action of non-stimulants at 
targeting the key neurotransmitter pathways and their receptors that are underlying the 
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pathogenesis of ADHD.  With this knowledge, the APPN can prescribe non-stimulants 
knowing that their mechanism of action can effectively target the pathophysiology of 
ADHD leading to improved symptoms.  In this review of literature, evidence-based 
research articles on atomoxetine (Strattera), clonidine ER (Kapvay), and guanfacine ER 
(Intuniv) will be discuss as well as their clinical outcomes.  
Definitions 
ADHD: An abbreviation for Attention Deficit Hyperactivity Disorder, which is a 
neurobehavioral disorder commonly of childhood onset with three primary symptoms of 
inattention, hyperactivity, and impulsivity (National Institute of Mental Health, 2017).      
Pediatric: Generalized term for the population of children and adolescents (National 
Institute of Mental Health, 2017).   
Children: Human being prior to puberty; ages 6-12 (National Institute of Mental Health, 
2017).     
Adolescents: Human being during the pubertal time; ages 13-18 (National Institute of 
Mental Health, 2017).    
ER: An abbreviation for “extended-release” formulation of a mediation, which causes a 
slow, controlled-release of a medication over a longer period of time. Similar names for 
extended-release are SR “sustained-release” and CR “controlled-release”.  In some 
publications one may see extended-release abbreviated as XR (Stahl, 2013).   
Effectiveness/efficacy: Producing the desired effect of a medication’s intention (Stahl, 
2013).   
Statistically significant: In research, the relationship of a study’s findings was not due to 
chance; p-value is less than 5% (Stahl, 2013).   
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Process 
A literary search was performed using the University of North Dakota’s Harley E. 
French Library of the Health Sciences to locate research articles on the effectiveness of 
non-stimulants for the treatment of ADHD in the pediatric population.  The search 
engines of PubMed, CINAHL, and PyscInfo were utilized due to their specialization in 
nursing, medicine, health, life, and psychology.   
The literature search began with PubMed with the use of MeSH (medical subject 
heading) terms and using limitation of the last 10 years, peer-reviewed, and English 
language.  The use of the MeSH terms “ADHD” AND “pediatric” AND “atomoxetine” 
resulted in 129 articles, “ADHD” AND “pediatric” AND “clonidine ER” resulted in 24 
articles, and “ADHD” AND “pediatric” AND “guanfacine ER” resulted in 39 articles.  A 
review of the titles, abstracts, and keywords within the articles were scanned and 21 
articles were found applicable to the literature review topic.  After reading the articles, 
eight were chosen for inclusion into the literature review portion of the paper.   
The CINAHL database was then searched using Boolean Connectors and 
CINAHL Headings and the limitations of 2007-2017, peer-reviewed, English language, 
and human subjects.  “ADHD” AND “pediatric” AND “atomoxetine” was searched and 
resulted in 17 articles, “ADHD” AND “pediatric” AND “clonidine ER” and resulted in 
two articles, and “ADHD” AND “pediatric” AND “guanfacine ER” and resulted in two 
articles.  After reviewing the articles, 13 were eliminated due to the content and age 
limitations not being congruent with the literature review topic and repetitive articles that 
were found during the PudMed search, leaving four articles that were chosen to be 
included in the paper.   
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PsycInfo was another database that was used to gather pertinent articles to the 
literature review topic with the use of Boolean Connectors with the same limitations as 
the CINAHL search.  “ADHD” AND “pediatric” AND “atomoxetine” was searched and 
resulted in 33 articles, “ADHD” AND “pediatric” AND “clonidine ER” and resulted in 
seven articles, and “ADHD” AND “pediatric” AND “guanfacine ER” and resulted in 
seven articles.  After reviewing the articles, 35 were found to not be applicable to the 
literature search topic or had repetitive data.  Six articles were found to be repeat articles 
of the ones found in the PubMed and CINAHL searches and they were eliminated, 
leaving three articles for inclusion in the paper.   
The information that is in this literature review has been obtained through the 
literature search, which is described above and has been formatted into an informative 
PowerPoint presentation (see Appendix).  The PowerPoint presentation will be emailed to 
the University of North Dakota Psychiatric Mental Health Nurse Practitioner student 
class of 2018.  Presenting this PowerPoint to this cohort during their senior year allows 
for the opportunity for them to share these findings during their clinical practicums. 
Increasing the knowledge of the effectiveness of non-stimulants for ADHD in the 
pediatric population to APPN’s allows for evidence-based treatment planning for their 
patients.   
Review of Literature 
According to the American Academy of Pediatrics (2011), children with ADHD 
over the age of 6 have a strong recommendation, quality of evidence level A 
(strongest/highest recommendation), to be prescribed a food and drug administration 
(FDA)-approved medication for ADHD and/or behavioral therapy.  Furthermore, these 
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guidelines state, “the evidence is particularly strong for stimulant medications and 
sufficient but less strong for atomoxetine, extended-release guanfacine, and extended-
release clonidine (in that order) (quality of evidence level A)”, (American Academy of 
Pediatrics, 2011, p. 2).  With the support of the FDA by their approval for atomoxetine, 
clonidine ER, and guanfacine ER as ADHD specific non-stimulants, the APPN should be 
knowledgeable regarding each of these medication’s unique outcomes in targeting the 
symptomology of ADHD in the pediatric population.  This literature review will analyze, 
critique, and summarize research articles that have addressed the effectiveness of these 
non-stimulants specifically in the pediatric population.   
Atomoxetine (Strattera)  
Two similar randomized control trials (RCTs) were found during this literature 
search that analyzed atomoxetine and a placebo.  The first was a randomized, double 
blind placebo-controlled trial, which was conducted with atomoxetine in children and 
adolescents from age ranges 6-16 years old with a DSM-IV diagnosis of ADHD to 
determine efficacy.  This trial took place in Russia, was 6-weeks long, and contained 105 
patients with 72 receiving atomoxetine and 33 receiving the placebo.  The results of this 
trial were statistically significant according to the Attention-Deficit/Hyperactivity 
Disorder Rating Scale-IV-Parent Version (ADHD-RS-IV-Parent) scores; which includes 
scales for inattention, impulsivity, and hyperactivity.  The comparative baseline to 
treatment response after 6 weeks for atomoxetine was 72.2% and the placebo 48.5% 
(Martenyi et al., 2010).  It was also noted that patients who received atomoxetine had a 
more rapid clinical outcome response.  
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Secondly, according to Weiss, Tannock, Kratochvil, Dunn, Velez-Borras, 
Thomason, & Allen (2005), atomoxetine was found to be effective in treating ADHD 
symptoms in a RCT using atomoxatine and a placebo in 153 children with ADHD ages 8-
12 years old.  A similar scale was used as the previously mentioned study, however 
instead of parents evaluating the child, the teacher did using the ADHD-RS-IV-Teacher 
scale.  This scale was administered at baseline and at 7 weeks resulting with the 
atomoxetine group having 69% decrease of at least 20% in symptoms of inattention, 
hyperactivity, and impulsivity compared to the placebo of 43.1% (Weiss, et al., 2005).  
As with the previously mentioned study, it was also found to have quick onset of 
symptom improvement starting at only one week.     
 Nagy, Häge, Coghill, Caballero, Adeyi, Anderson, and Cardo (2016) found 
another way to determine effectiveness of atomoxetine in children with ADHD by using 
the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P).  In doing so, a 
randomized control, double-blinded trial of atomoxetine and lisdexamfetamine 
dimesylate was performed with 200 children with ADHD from ages 6 to 17 years old.  
For the focus of this literature review, only atomoxetine’s effectiveness will be analyzed.  
The WFIRS-P “comprises 50 items, grouped into six domains (Family, Learning and 
School, Life Skills, Child’s Self-Concept, Social Activities, and Risky Activities)” and 
was administered to parents or guardians at baseline and at 9 weeks (Nagy, et al., p.143, 
2016).  Atomoxetine was found to have statistically significant results showing a 
decrease in all six domains of the WFIRS-P with the largest decrease in the family, 
learning, and school domains.   
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 An important limitation of these studies to note is their short duration of less than 
12 weeks.  Atomoxetine can take up to 12 weeks or more to reach maximum potential, 
therefore, any study that is less than 12 weeks may be not be resulting in the full 
treatment potential that atomoxetine has (Nagy, 2016).  Subjective scales can also limit 
some of the studies validity due to its openness for human interpretation and subjectivity; 
however, due to the nature of the ADHD’s symptomology it would be difficult to 
eliminate this bias.  Strengths of the studies include the research designs of randomized 
blinded studies and specific patient populations and diagnoses.  There remain gaps in the 
research for making more specific outcome measurement scales that are more inclusive 
of the patient’s report, larger patient populations, and longer duration of studies.    
A more recent study by Nakanishi, Ota, Iida, Yamamuro, Kishimoto,	Okazaki,	&	Kishimoto	(2017) utilized a more objective tool to measure the effectiveness of 
atomoxetine and the stimulant medication of methylphenidate.  Oxyhemoglobin level 
measured by near-infrared spectroscopy (NIRS) was obtained during a stroop color-word 
test on 30 children with a diagnosis of ADHD ages 6-14.  A probe was placed over the 
patient’s frontal orbital regions to obtain oxyhemoglobin levels, which indicates 
prefrontal cortex activity. Levels were obtained every 0.1 seconds throughout the stroop 
color-word test, with readings averaged over 10 seconds.  NIR measurements were 
obtained pre-treatment and 12 weeks after atomoxetine was started, which is a strength of 
the study by having a long enough time frame to match the therapeutic effects of 
atomoxetine. However, a major limitation was the small number of participants and their 
treatment group was not randomly assigned, a pediatric psychiatrist assigned them (with 
methodology unknown).      
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The results of the actual stroop word-color test was also analyzed which is an 
indicator of selective attention in execute functioning, known to be decreased in children 
with ADHD.  There were statistically significant improvements in the stroop color-word 
test from pre-medication to 12 weeks after starting atomoxetine.  It was also noted that 
there was positive correlation between age and scores.  Furthermore, the NIRS 
oxyhemoglobin levels had substantial increases from pre-medication to 12 weeks after 
the start of atomoxetine.  More specifically, the left lateral frontal lobe had the greatest 
increase in oxyhemoglobin levels.  Interesting to note, although beyond the scope of this 
literature review, methylphenidate did not show any improvement in oxyhemoglobin 
levels (Nakanishi et al., 2017).    
The meta-analysis by Schwartz & Correll (2014) helped pull together results of 25 
double-blinded RCTs that used atomoxetine and a placebo with children with ADHD.    
Again, the results favored atomoxetine over the placebo, 44.6% of patients had 
improvement of symptoms of 40% or higher.  However, there were 39.9% of patients 
who did not respond with over 25% improvement of their symptoms.  The results were 
similar throughout the childhood years and results did not differ from children to 
adolescents.  Therefore, the authors agreed that there are patient specific factors that need 
further research in why some pediatric patients respond well and other do not.  When 
reviewing the studies, the authors felt that limitations for this RCT is generalizing the 
results to the whole pediatric ADHD population because only certain patients may be 
exposed to the opportunity to participate in these studies.  	
 Clinical trials, as mentioned above, have shown atomoxetine to be effective at 
targeting the core symptoms of ADHD in children.  There are factors that affect 
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atomoxetine’s effectiveness.  In order for atomoxetine to be effective it must be dosed 
appropriately and maintained in a therapeutic window.  Children who lack the CYP2D6 
enzymatic pathway or are rapid metabolizers will have a difficult time metabolizing the 
medication and maintaining that therapeutic window; therefore, the FDA makes 
prescribers aware of these dosing instructions for CYP2D6 sensitive children on its 
packaging label (Dean, 2012).    
 A review of literature by Kohn, Tsang, & Clarke (2012) concluded atomoxetine to 
be efficacious in children who also have anxiety or tic related disorders.  The efficacy 
also was not altered by other comorbid conditions and allowed for atomoxetine to 
maintain a therapeutic effect.  In addition, health related quality of life results were 
positively correlated with short and longer-term studies of atomoxetine in children with 
ADHD.   
Clonidine ER (Kapvay) 
  Clonidine ER, the generic form is labeled Kapvay, is the only formulation of 
clonidine that is approved by the FDA for the treatment of ADHD in the pediatric 
population (immediate release is not).  A systemic review by Chan, Fogler, & 
Hammerness (2016) found clonidine ER effective as monotherapy and as an adjunct with 
stimulants therapy for children with ADHD ages 6-17.  Studies regarding the effects of 
clonidine ER monotherpay are limited due to a greater interest in clonidine ER/stimulant 
combination therapy.   
As with atomoxetine, there was been a couple statistically significant RCTs 
performed using a placebo-control to determine the effectiveness of clonidine ER.  A 
shorter RCT of only 8 weeks compared clonidine ER and a placebo looking at various 
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aspects of ADHD in children ages 6-17 years old.  Statistically significant improvements 
were found between pre-medication and at the 8-week mark on scales of ADHD-RS-IV, 
Conner’s Parent Rating Scale, Parent Global Assessment, and Clinical Global Impression 
of Improvement and Severity Scales.  As with atomoxetine, clonidine ER demonstrated a 
quick response to treatment starting as soon as two weeks.  A major limitation of this 
study is the short duration of the study and that it only had a sample size of 236 patients.  
The study also required same dose titrations during this 8-week period; which limits the 
individual therapeutic needs of the patient (Jain, Segal, Kollins, & Khayrallah, 2011).  
Palumbo, Sallee, Pelham, Bukstein, Daviss, & McDermott, (2008) published a 
slightly longer RCT of 16 weeks, which strengthens the study, however, it was performed 
on only 122 children ages 7-12, which then limits the study due to its small size.  
Clonidine ER, methylphenidate, or a combination of the two medications were analyzed 
at pre-medication and every 4 weeks for a total of 16 weeks using 3 different scales: 
Conners Teachers Abbreviated Symptom Questionnaire, Conner’s Abbreviated Symptom 
Questionnaire for Parents and Children's Global Assessment Scale.   
Each scale produced differing results regarding the efficacy of clonidine ER.  The 
Conner’s Teachers Abbreviated Symptom Questionnaire did not result in improvement of 
ADHD symptoms in the clonidine ER monotherapy group, but did show improvement in 
the combination of clonidine ER/methylphenidate group.  The Conner’s Abbreviated 
Symptom Questionnaire for Parents and Children's Global Assessment Scale however did 
show improvement in ADHD symptoms whether it was in the clonidine ER monotherapy 
group or the combination group.  Even though the results were not robust for clonidine 
ER, the authors believe clonidine ER is efficacious for certain ADHD patient subtypes 
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such as those with co-morbid behavioral and/or impulsive disorders (Palumbo et al., 
2008).   
To look even further into the efficacy of adding clonidine ER to stimulants, 
Kollins, Jain, Brams, Segal, Findling, Wigal,	&	Khayrallah,	(2011), published a 
randomized double-blinded trial that used either clonidine ER or a placebo to a current 
stimulant treatment plan that was not effective.  Clonidine ER was not evaluated as 
monotherapy.  There were a total of 198 children and adolescents enrolled over this 8-
week study.  A strength of this study was reported to be a diverse patient population of 
males, females, children and adolescents.  Limitations include excluding comorbid 
disorders; which eliminates many of the ADHD populations that have co-existing 
learning or behavioral disorders, and the variability in stimulant medications.  	
The ADHD-RS-IV scale was administered at baseline, week 2, week 5, then 
weekly through out the 8 week study.  At week 2 there was no differences from baseline 
scores between the clonidine ER combination group and the placebo combination group.  
Starting at week 5 the clonidine ER combination group started to show statistically 
significant results, which continued throughout the remainder of the study.  Hyperactivity 
and inattention subscale scores with the ADHD-RS-IV were analyzed showing statistical 
significant is these subcategories.  To strengthen this study, the Conner Parent Rating 
Scale, Clinical Global Impression of Severity and Improvement, and Parent Global 
Assessment were also analyzed at the same week intervals as the primary ADHD-RS-IV 
scale and were all found to have statistically significant improvements in their scores for 
the clonidine ER combination group (Kollins et al., 2011).    
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Guanfacine ER (Intuniv) 
 In 2009, the FDA approved the extended release form of guanfacine ER called 
Intuniv.  A literature review by Strange (2008) found guanfacine ER to have profound 
effects on executive functioning in children by improved attention spans, impulse control, 
planning, working memory, and distractibility.  This is in support of the theory of 
guanfacine’s mechanism of action working in the prefrontal cortex.  Improvements in 
behaviors and motor control can be attributed to guanfacine’s effects on the 
noradrenergic projections to the basal ganglia and cerebellum.   
 Two RCTs had profound impacts on the FDA decision to approve guanfacine ER 
in the pediatric population for ADHD.    Sallee et al. (2009) published an RCT that was a 
double-blinded comparison of guanfacine ER and a placebo; the guanfacine ER group 
was divided into 3 separate dosage groups.  Three hundred twenty-nine children and 
adolescents aged 6 to 17 years old were evaluated with the ADHD-RS-IV scale prior to 
the start of the trial and 9 weeks after the start of the trial.  Averaged improvements in 
ADHD-RS-IV was reported for all three guanfacine ER dosage groups showing a 
reduction in score of 19.6, compared to the placebo which had a reduction of 12.2.  More 
specifically, the subscales of the ADHD-RS-IV scale in categories of inattention, 
hyperactivity, and impulsivity, all had significantly improved scores in the guanfacine ER 
groups over the placebo group.  Strict inclusion and exclusion criteria were strengths of 
the study with limitations included a short 9-week trial duration and a small number of 
adolescents compared to children (Sallee et al., 2009).   
 A very similar double-blind RCT of 345 children and adolescents (ages 6-17 
years old) also compared guanfacine ER with 3 different dosage groups and a placebo.  
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Efficacy was also determined using the ADHD-RS-IV scale prior to the start of the trial 
and at 8 weeks.  Again, subscales for inattention, hyperactivity, and impulsivity were 
analyzed with all categories resulting in statistically significant improvement in the 
guanfacine ER groups.  The average changes in scores for the guanfacine ER groups 
were 17.16 and the placebo group was 8.48 (Biederman, Melmed, Patel, McBurnett, 
Konow,  Lyne, & Scherer, 2008).  This study also used secondary efficacy scales of 
Clinical Global Impression of Improvement, Parent's Global Assessment, Conner’s 
Parent and Teacher Rating Scale–Revised, and Conner’s' Teacher Rating Scale–Revised 
and found significant improvements in the guanfacine ER groups.  Again, this study was 
limited by its short duration.  	
 These two RCTs provided valid statistically significant results as indicated by the 
ADHD-RS-IV scale and subscales.  Monotherapy for guanfacine ER for ADHD in the 
pediatric population was found to be efficacious.  A literature review by Faraone, 
McBurnett, Sallee, Steeber, & López (2013) found varying results in the efficacy onset of 
action for guanfacine ER, ranging from 1-4 weeks.  In addition, guanfacine ER was 
found to be favorable for pediatric patients with ADHD that had dominant oppositional 
symptoms.   
 In 2011, the FDA approved guanfacine ER as an adjunct to stimulant treatment 
for pediatric patients with ADHD aged 6-17.  This combination was found to be 
beneficial in children who were not experiencing the full treatment potential of stimulant 
medications.  In addition, ADHD-RS-IV scores saw improvements with guanfacine 
ER/stimulant combination therapy in children with opposition symptoms and those 
without (Childress & Berry, 2012). 
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 The pivotal RCT approving guanfacine ER/stimulant combination treatment 
efficacious, was published by Wilens, Bukstein, Brams, Cutler, Childress, Rugino, & 
Youcha, (2012).  This was a larger scale study of 461 participants of children and 
adolescents with ADHD aged 6-17.  It was double-blinded with participants randomly 
adding either guanfacine ER or a placebo to their current stimulant medication.  A 
strength of this study was that it also used the ADHD-RS-IV scale, which has been 
commonly used in other ADHD medication trials.  A limitation of this study was the 
possible difficulty of assessing efficacy because a requirement was for a partial response 
in stimulant therapy already before entering the trial.  A shorter duration of 9 weeks was 
another reported limitation.   
  Scores from the ADHD-RS-IV scale and subscales, in addition, Clinical Global 
Impressions of Severity of Illness and Improvement scales were averaged for the 
guanfacine ER/stimulant group and placebo/stimulant group.  There were significant 
improvements in scores for all assessment scales for the guanfacine ER/stimulant group 
verses the placebo/stimulant group.  The study had also compared morning and evening 
doses of each treatment group.  When analyzing the guanfacine ER/stimulant treatment 
group, there were no differences in assessment scales for efficacy whether the medication 
was administered in the am or pm.  Overall, guanfacine ER was shown effective as an 
adjunct to stimulant therapy for children and adolescents with ADHD (Wilens et al., 
2012).     
Results 
The comprehensive literature search through CINAHL, PubMed, and PsycInfo 
resulted in 15 articles that were reviewed, evaluated, and deemed relevant to the literature 
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review topic of the effectiveness of non-stimulants in the treatment of ADHD in the 
pediatric population.  A summary of the type of studies within these 15 articles include 
nine RCTs, three literature reviews, one non-randomized study, one meta-analysis, and 
one systemic review.  RCT studies were found to be very beneficial because there was 
elaboration on the specific types of outcome measurement tools that were utilized.  The 
most common scale that was used was the ADHD-RS-IV-Parent and the Clinical Global 
Impression and Severity Scale.  Other scales that were also utilized were the ADHD-RS-
IV-Teacher, WRIRS-P, Connors Parents and Teacher Rating Scale, and the Parent Global 
Scale.  Most of these scales had either a parent/guardian or teacher completing the scale.  
The non-randomized study did not use a scale; the Stroop Word-Color Test and NIRS 
score was performed instead.    
Six out of 15 chosen articles studied the effectiveness of atomoxetine with all in 
agreement of atomoxetine as being an effective medication for the treatment of ADHD in 
the pediatric population.  The articles had statistically significant results supporting 
atomoxetine’s effectiveness and two found atomoxetine to have more rapid onset than the 
placebo. One study found the NIRS (near-infrared spectroscopy) exam to have increased 
prefrontal cortex activity especially in the left lateral frontal lobe when on atomoxetine.   
Four out of the total 15 articles found clonidine ER to have statistically significant 
results supporting its efficacy for the treatment of ADHD in the pediatric population.  
Two out of the three RCT’s compared the effectiveness of clonidine ER as an adjunct 
medication to stimulant treatment.  The systemic review highly supported the use of 
clonidine ER as an adjunct medication to stimulant therapy and found clonidine ER to be 
more helpful with behavioral symptoms.   
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Five out of the total 15 articles also found guanfacine ER to have statistically 
significant results.  Guanfacine ER was found to be an effective adjunct to stimulant 
treatment in 3 out of the 5 articles.  One article found guanfacine ER to be specifically 
efficacious in children with oppositional symptoms.   
All 15 articles found atomoxetine, clonidine ER, and guanfacine ER as effective 
non-stimulants to treat ADHD in the pediatric population.  The scales that were utilized 
measured inattention, hyperactivity, and impulsivity; also, depending on the scale, 
measured domains such as family, social, and psychological symptoms.  These outcome 
measurement scales varied between research studies; however, due to their similar 
outcomes they were measuring, their outcomes were found to be clinically significant.  
The PowerPoint presentation (see Appendix) will include these results along with all the 
other sections of this paper and will be delivered to the University of North Dakota 
Psychiatric Mental Health Nurse Practitioner student class of 2018.  The purpose of this 
literature review is to increase knowledge therefore feedback regarding this literature 
review is not required but is welcomed.  
Discussion of Implications in Nursing  
Practice 
 Implications of this literature review can impact the APPN’s practice by 
providing the APPN with knowledge to deliver holistic patient-centered care.  The 
decision to choose non-stimulants over the best practice guideline of stimulants, can 
demonstrate how the APPN is providing holistic care by addressing all aspects of the 
patients needs and concerns.  When parents/guardians refuse for their child to be 
medicated for ADHD, it is important to explore their concerns and assess their 
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knowledge regarding available FDA approved ADHD medications for children and 
adolescents.  Parents/guardians may not be aware that non-stimulant medications can 
effectively treat ADHD in the pediatric population; therefore, the APPN should offer a 
complete review of medication alternatives.  The content of this literature review was not 
conclusive to determine if a non-stimulant should be prescribed, rather it reviews an 
option for treatment.  Additional factors when prescribing that go beyond the scope of 
this literature review should be assessments for side effects, drug interactions, co-existing 
medical conditions, allergies, etc.   
 Due to the potential adverse outcomes that can occur if children and adolescents 
are not effectively treated for ADHD, the APPN should strive for providing the most up-
to-date, comprehensive, knowledgeable care.   It is important to not become stagnant in 
one’s practice.  Continuing to educate oneself is essential as new evidence-based research 
becomes published and understanding of the brain and how it relates to mental illness is 
ever increasing.   
Research 
The literature search and review of articles did reveal quantity and quality of 
research on the topic of non-stimulant effectiveness for ADHD treatment in the pediatric 
population.   There was an abundance of research regarding stimulant treatment for 
ADHD and ADHD treatment for adults not used in this review.  The literature search 
resulted in 15 articles that were specific to the ADHD pediatric population, which was 
very small compared to the search for the adult ADHD population.  Furthermore, there 
was difficulty in finding research that was purely measuring the effectiveness of a non-
stimulant.  Many articles evaluated stimulant therapy and/or stimulant with adjunct non-
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stimulant therapy.  This was found to be particularly true when researching clonidine ER 
and guanfacine ER.  These two non-stimulants had more research regarding their 
effectiveness when used as an adjunct with stimulants than atomoxetine did.  Additional 
research would be beneficial to support clonidine ER and guanfacine ER as monotherapy 
medication treatment for ADHD in children and adolescents.   
Even though the research articles provided statistically significant results, there 
was contrast throughout studies regarding outcome measurement scales.  To ensure 
consistency and validity in research, standardized outcome measurement scales would be 
preferred.  Interesting to note, most scales used were given to parent/guardians or 
teachers.  More research is needed to determine what outcome measurement scale is best 
to determine effectiveness of a medication for pediatric patients with ADHD.  A scale 
that also incorporates the patient’s input may be useful.   
In addition, limitations within each study could be improved upon.  Sample size 
and duration of study were common limitations that are mendable.  With the 
understanding of non-stimulant’s mechanism of action in regards to duration time of peak 
effectiveness, proper study durations could be utilized.  It is common for studies to have 
smaller sample sizes for pediatric research patients due to ethical concerns.  However, 
larger samples sizes will increase validity and statistically significant results.  Ongoing 
research is necessary to keep information current on the effectiveness of these and other 
medications for the treatment of ADHD.  
Education 
 The purpose of this literature review is to give education to APPNs by providing 
information on the effectiveness of non-stimulants for children and adolescents with 
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ADHD.  By presentation of a PowerPoint prepared educational tool, APPNs may gain 
knowledge of the research articles that have been published which have contributed to the 
FDA’s decision to approve atomoxetine, clonidine ER, and guanfacine ER as non-
stimulant treatment for ADHD in the pediatric population.  The knowledge gained from 
this educational tool can be used for increasing the treatment options of children and 
adolescents with ADHD.    
 Understanding the mechanism of action of the non-stimulants, as described 
previously, is important when determining what medication is best for a patient.  It is 
important for the APPN to be educated on medications, including their evidence-based 
research.  That knowledge can be used not only for treatment decisions but also for 
providing pyschoeducation to their patients (American Nurses Association, 2014).  With 
knowledge of the evidence-based research, the APPN can educate the patient and their 
parents/guardians regarding its effectiveness and how the medication will target the core 
symptoms of ADHD.       
Health Policy 
 Implications of the findings of this literature review can be used as part of an 
educational tool to make changes to health policies at varying levels.  Policies at 
hospitals, outpatient settings, and state levels can be impacted by the results of this 
literature review by APPN’s advocating for updated policies for treatment options.  
Furthermore, the APPN can support continuing research by seeking out research studies 
and supporting their clients they choose to enroll.   
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Conclusion 
ADHD is a complex disorder with the potential to leave profound effects on one’s 
childhood and development when not treated effectively. This literature review focused 
on the effectiveness of non-stimulants for the treatment of ADHD in the pediatric 
population and found statistically significant results supporting their use.  The literary 
search of atomoxetine, clonidine ER, and guanfacine ER found statistically significant 
results despite the use of differing yet similar outcome measurement scales.  Even though 
the research proved significant results, which helped support the FDA in approving these 
non-stimulants for the treatment of ADHD in children and adolescents, continuing 
research is need to maintain these medications as treatment options for this population. 
The reviewed research studies were found to have limitations due to their short study 
duration.  There is a need for more research studies with longer duration, greater sample 
size, and with a focused monotherapy experimental group to strength the validity of their 
findings.   
 With the results of this literature review and the developed educational 
PowerPoint tool, the APPN can make more knowledgeable decisions during treatment 
planning for their pediatric patient with ADHD.  In addition to the APPN having 
increased knowledge to make their educated decision, the APPN will also have another 
educational tool to utilize during medication education with parent/guardians and the 
patient.  The APPN will be equipped to engage in comprehensive treatment planning with 
families. Providing optimal quality of care to children and adolescents with ADHD gives 
these clients the opportunity for growth and development similar to their peers not 
affected by this condition. This literature review demonstrates that APPNs need to stay 
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informed of current research findings on ADHD treatment and support ongoing research 
of evidence-based treatment options in this area.  It would be anticipated that APPNs who 
empower themselves with this type of knowledge would have professional growth and 
satisfaction in delivering care to pediatric patients with ADHD.   
 
 
 
 
 
 
 
 
 
  
EFFECTIVENESS OF NON-STIMULANTS FOR ADHD                                             30      
Appendix	
 
Effectiveness	of	Non-Stimulants		for	the	Treatment	of		Attention	De8icit	Hyperactivity	Disorder		in	the	Pediatric	Population			
This	is	a	presenta,on	of	a	literature	review	by:	
Rebecca	Gonzalez,	Psychiatric	Mental	Health	Nurse	Prac,,oner	student		
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Introduction	to	ADHD	
•  Neurobehavioral/
neurodevelopmental	
disorder		
•  Primarily	of	childhood	
onset		
•  Core	symptoms:	
ina:en;on,	
hyperac;vity,	
impulsivity		
•  Core	symptoms	are	
targeted	by	
pharmacology		
						(Na;onal	Ins;tute	of	Mental	Health,	2017)		
	
•  According	to	the	
American	Psychiatric	
Associa;on	(2013),	5%	
of	children	have	ADHD		
•  There	is	new	criteria	
for	ADHD	in	the	DSM-
V,	thus	it	is	es;mated	
that	the	prevalence	
may	be	closer	to	8-12%		
						(Botero-Franco,	Palacio-Or;z,	Arroyave-Sierra,						
							&	Pineros-Or;z,	2016)	
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Introduction	to	the	use	of	non-stimulants	for	ADHD	
•  There	is	a	28%	increase	in	the	pharmacological	
treatment	of	ADHD	in	children	from	2007	to	2012	
(Centers	for	Disease	Control	and	Preven@on,	2017)	
•  Implica@on	of	ineffec@ve	treatment	include:	
difficulty	with	school	performance,	socializing	with	
others,	coping	skills,	&	there	is	an	increased	risk	for	
substance	abuse	and	other	co-morbid	learning	and	
behavioral	disorders	(Shier,	Reichenbacher,	Ghuman,	&	Ghuman,	2013)	
•  Use	of	non-s@mulants	is	increasing	due	to…the	
increasing	diagnoses	of	ADHD,	increased	
pharmacological	treatment,	and	concern	over	
s@mulants	
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This	literature	review	analyzed	the	effec4veness	of	the		
3	FDA	approved	non-s4mulants		
atomoxe4ne	(StraAera)	
	clonidine	ER	(Kapvay)	
	guanfacine	ER	(Intuniv)	
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Purpose	
Provide	APPNs	with	current	evidence-based	knowledge	on	the	
effec9veness	of	non-s9mulants	to	guide	their	prescribing	decisions	for	
the	treatment	of	ADHD	in	the	pediatric	popula9on		
This	knowledge	is	per0nent	for	APPNs	to	follow	their	Scope	and	
Standards	of	Prac0ce	by	the	American	Nurses	Associa0on		
•  8th	Standard	of	Prac0ce-EDUCATION:	APPN	u0lizes	evidence-based	
research	findings	to	enhance	clinical	knowledge		
•  10th	Standard	of	Prac0ce-QUALITY	OF	PRACTICE:	Enhancing	the	
APPN’s	knowledge	to	improve	their	quality	of	care,	improving	their	
prescrip0ve	decision-making	process	and	therefore	enhancing	the	
outcome/effec0veness	of	the	treatment	of	ADHD	in	the	pediatric	
popula0on		
•  5D	Standard	of	Prac0ce-PRESCRIPTIVE	AUTHORITY	and	TREATMENT:	
To	be	knowledgeable	in	medica0on’s	efficacy,	side	effects,	mechanism	
of	ac0ons,	and	the	consumers	individualized	needs	when	using	their	
prescrip0ve	authority		
(American	Nurses	Associa0on,	2014)		
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Signi%icance	
•  Using	s'mulants	to	treat	ADHD	in	children	has	been	well	
researched	and	proven	to	be	highly	effec've,	however,	they	
hold	an	abuse	poten'al	and	cause	many	undesirable	side	
effects	that	cause	clinicians	and	parents	to	prefer	not	to	use	
these	medica'ons	and	look	to	non-s'mulants		
						(Mar'nez-Raga,	Ferreros,	Knecht,	De	Alvaro,	&	Carabal,	2017)		
•  American	Academy	of	Pediatrics	has	a	strong	
recommenda'on	for	children	and	adolescents	to	be	treated	
with	FDA	approved	ADHD	medica'ons		
						(American	Academy	of	Family	Physicians,	2017)		
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Signi%icance	
It	is	highly	important	to	know	how	to	effec5vely	treat	ADHD	in	
the	pediatric	pa5ent	due	to	ADHD’s	poten5al	nega5ve	
outcomes	that	sustain	throughout	childhood	and	extend	into	
adulthood	which	are…	
	
•  Poorer	academic	performance	which	leads	to	an	increased	
risk	for	failing	or	dropping	out		
•  Rela5onship	difficul5es	with	peers	and	family	members		
•  Poorer	working	memory		
•  More	likely	to	have	legal	and	substance	abuse	problems		
•  More	prone	to	injuries		
•  Increased	risk	for	other	comorbid	mental	health	disorders		
(Riera,	Castells,	Tobias,	Cunill,	Blanco,	&	Capella,	2017;	Roman-Urrestarazu	et	al.,	2016;	Kovshoff,	Williams,	Vrijens,	
Danckaerts,	Thompson,	Yardley,	&	Sonuga-Barke,	2012;	Na5onal	Ins5tute	of	Mental	Health,	2017	)		
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Theoretical	Framework	
APPN	should	understand	the	pathophysiology	of	the	disease	
(ADHD)	itself.		A	prescriber	can	then	choose	a	medica=on	that	
has	a	mechanism	of	ac=on	that	targets	the	pathophysiology	of	
the	disease		
•  Understanding	the	role	of	the	dopamine	(DA)	and	
norepinephrine	(NE)	and	their	receptors	in	ADHD	is	essen:al	
to	guide	the	APPN’s	prescribing	decision-making		
•  Symptomology	of	ADHD	not	only	results	from	a	decrease	DA	
and	NE	but	also	can	results	from	an	excessive	amount,	
therefore,	there	needs	to	be	a	moderate	level	of	both	DA	and	
NE	for	proper	prefrontal	cortex	func:oning	thus	improving	
the	symptoms	of	ADHD	
•  Overall,	there	should	be	a	moderate	amount	of	DA	to	their	D1	
receptors	and	moderate	amount	of	NE	to	their	a2A	receptors		
(Banaschewski	et	al.,	2005;	Stahl,	2013)		
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De#initions	
ADHD:	An	abbrevia*on	for	
A-en*on	Deficit	Hyperac*vity	
Disorder,	which	is	a	
neurobehavioral	disorder	
commonly	of	childhood	onset	with	
three	primary	symptoms	of	
ina-en*on,	hyperac*vity,	and	
impulsivity	
			
Pediatric:	Generalized	term	for	the	
popula*on	of	children	and	
adolescents	
			
Children:	Human	being	prior	to	
puberty;	ages	6-12	
		
Adolescents:	Human	being	during	
the	pubertal	*me;	ages	13-18.		
ER:	An	abbrevia*on	for	“extended-
release”	formula*on	of	a	
media*on,	which	causes	a	slow,	
controlled-release	of	a	medica*on	
over	a	longer	period	of	*me.	Similar	
names	for	extended-release	are	SR	
“sustained-release”	and	CR	
“controlled-release”.		In	some	
publica*ons	one	may	see	extended-
release	abbreviated	as	XR	
	
Effec7veness/efficacy:	Producing	
the	desired	effect	of	a	medica*on’s	
inten*on	
			
Sta7s7cally	significant:	In	research,	
the	rela*onship	of	a	study’s	findings	
was	not	due	to	chance.		The	p-value	
is	less	than	5%.			
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Process	
U"lized	the	University	of	North	Dakota’s	Harley	E.	French		
Library	of	the	Health	Sciences		
	
Search	Engines	and	results…	
u PubMed:	8	ar"cles	were	chosen	for	inclusion	into	the	
literature	review		
•  Limita"ons:	last	10	years,	peer-reviewed,	and	English	language	
•  MeSH	terms:	“ADHD”	AND	“pediatric”	AND	“atomoxe"ne”	
resulted	in	129	ar"cles,	“ADHD”	AND	“pediatric”	AND	“clonidine	
ER”	resulted	in	24	ar"cles,	and	“ADHD”	AND	“pediatric”	AND	
“guanfacine	ER”	resulted	in	39	ar"cles		
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Process	
u CINAHL:	4	ar%cles	that	were	chosen	to	be	included	in	the	literature	
review	
•  Limita%ons:	2007-2017,	peer-reviewed,	English	language,	and	human	
subjects		
•  Boolean	Connectors	and	CINAHL	Headings:	“ADHD”	AND	“pediatric”	
AND	“atomoxe%ne”	was	searched	and	resulted	in	17	ar%cles,	
“ADHD”	AND	“pediatric”	AND	“clonidine	ER”	and	resulted	in	two	
ar%cles,	and	“ADHD”	AND	“pediatric”	AND	“guanfacine	ER”	and	
resulted	in	two	ar%cles	
	
u PsycInfo:	3	ar%cles	that	were	chosen	to	be	included	in	the	literature	
review	
•  Limita%ons:	2007-2017,	peer-reviewed,	English	language,	and	human	
subjects		
•  Boolean	Connectors:	“ADHD”	AND	“pediatric”	AND	“atomoxe%ne”	
was	searched	and	resulted	in	33	ar%cles,	“ADHD”	AND	“pediatric”	
AND	“clonidine	ER”	and	resulted	in	seven	ar%cles,	and	“ADHD”	AND	
“pediatric”	AND	“guanfacine	ER”	and	resulted	in	seven	ar%cles		
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Review	of	Literature		
	
	
Strong	recommenda*on,	level	A	to	be	prescribed	a	FDA	
approved	medica*on	for	ADHD	and/or	behavioral	therapy		
“The	evidence	is	par*cularly	strong	for	s*mulant	medica*ons	
and	sufficient	but	less	strong	for	atomoxe*ne,	extended-release	
guanfacine,	and	extended-release	clonidine	(in	that	
order)”	(American	Academy	of	Pediatrics,	2011,	p.	2)		
  
EFFECTIVENESS OF NON-STIMULANTS FOR ADHD                                             42      
 
Literature	Review:		
Atomoxetine	(Strattera)			v Double	blind	placebo-control	Randomized	Control	Trial	(RCT):	
•  Children/adolescents	aged	6-16	years	old	with	ADHD		
•  Took	place	in	Russia	
•  DuraDon	of	6-weeks	long		
•  Contained	105	paDents	with	72	receiving	atomoxeDne	and	33	
receiving	the	placebo		
•  Results	of	this	trial	were	staDsDcally	significant	according	to	the	
ANenDon-Deficit/HyperacDvity	Disorder	RaDng	Scale-IV-Parent	
Version	(ADHD-RS-IV-Parent)	scores		
•  ComparaDve	baseline	to	treatment	response	aSer	6	weeks	for	
atomoxeDne	was	72.2%	and	the	placebo	48.5%		
•  PaDents	who	received	atomoxeDne	had	a	more	rapid	clinical	
outcome	response		
(Martenyi	et	al.,	2010)		
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Literature	Review:		
Atomoxetine	(Strattera)		
v Double	blind	placebo-control	RCT	
•  153	children	with	ADHD	ages	8-12	years	old		
•  7	week	duraBon	
•  ADHDRS-IV-Teacher	scale		
•  AtomoxeBne	group	having	69%	decrease	of	at	least	20%	in	
symptoms	of	inaNenBon,	hyperacBvity,	and	impulsivity	compared	
to	the	placebo	of	43.1%		
•  AtomoxeBne	was	found	to	have	quick	onset	of	symptom	
improvement	starBng	at	only	one	week	
					(Weiss,	et	al.,	2005)	
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Literature	Review:		
Atomoxetine	(Strattera)		
v Double	blind	RCT	comparing	Stra6era	and	Vyvanse	
•  200	children	with	ADHD	from	ages	6	to	17	years	old		
•  DuraEon	of	9	weeks	
•  Used	the	Weiss	FuncEonal	Impairment	RaEng	Scale-Parent	
Report	(WFIRS-P)		
•  AtomoxeEne	was	found	to	have	staEsEcally	significant	results	
showing	a	decrease	in	all	six	domains	of	the	WFIRS-P	with	the	
largest	decrease	in	the	family,	learning,	and	school	domains		
u LimitaEons	of	these	RTCs:	short	duraEon	(atomoxeEne	can		
take	up	to	12	weeks	or	more	to	reach	maximum	potenEal),	
subjecEve	scales,	sample	size	
u Strengths	of	these	RTCs:	research	designs	of	randomized	
blinded	studies,	specific	paEent	populaEons,	and	diagnoses		
(Nagy,	2016)		
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Literature	Review:		
Atomoxetine	(Strattera)		
v Non-randomized	trial	measured	the	effec4veness	of	atomoxe4ne	
and	the	s4mulant	medica4on	methylphenidate		
•  30	children	with	a	diagnosis	of	ADHD	ages	6-14		
•  12	week	dura4on	
•  Oxyhemoglobin	levels	measured	by	near-infrared	spectroscopy	
(NIRS)	was	obtained	during	a	Stroop	Color-Word	Test		
•  Sta4s4cally	significant	improvements	in	the	stroop	color-word	test		
•  Results	showed	a	posi4ve	correla4on	between	age	and	scores		
•  NIRS	oxyhemoglobin	levels	had	substan4al	increases	from	pre-
medica4on	to	12	weeks	aQer	the	start	of	atomoxe4ne		
u Limita4ons:	small	sample	size	and	their	treatment	group	was	not	
randomly	assigned	(assigned	by	a	pediatric	psychiatrist)	
u Strength:	dura4on	of	study	matched	dura4on	for	max	effect	of	
atomoxe4ne	
(Nakanishi	et	al.,	2017)		
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Literature	Review:		
Atomoxetine	(Strattera)		
v Meta-analysis	of	25	double-blinded	RCTs	that	compared	
atomoxe<ne	and	a	placebo		
•  Results	favored	atomoxe<ne	over	the	placebo,	44.6%	of	pa<ent	
had	improvement	of	symptoms	of	40%	or	higher		
•  There	were	39.9%	of	pa<ent	who	did	not	respond	with	over	25%	
improvement	of	their	symptoms		
•  Results	did	not	differ	from	children	to	adolescents		
	
u Limita<ons	for	the	RCTs:	generalizing	the	results	to	the	whole	
pediatric	ADHD	popula<on	because	only	certain	pa<ents	may	
be	exposed	to	the	opportunity	to	par<cipate	in	these	studies	
				(Schwartz	&	Correll,	2014)		
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Literature	Review:		
Atomoxetine	(Strattera)		
v Literature	Review	
•  Atomoxe0ne	was	found	to	be	efficacious	in	children	who	also	
have	anxiety	or	0c	related	disorders		
•  Efficacy	was	not	altered	by	other	comorbid	condi0ons		
•  Health	related	quality-of-life	results	were	posi0vely	correlated	
with	short	and	longer	term	studies		
•  Children	who	lack	the	CYP2D6	enzyma0c	pathway	or	are	rapid	
metabolizers	will	have	a	difficult	0me	metabolizing	atomoxe0ne	
				(Kohn,	Tsang,	&	Clarke,	2012)		
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Literature	Review:		
Clonidine	ER	(Kapvay)		v Systemic	Review	
•  Found	clonidine	ER	effec5ve	as	monotherapy	and	as	an	adjunct	
with	s5mulant	therapy	for	children	with	ADHD	ages	6-17		
				(Chan,	Fogler,	&	Hammerness,	2016)		
v Double-blind	placebo-control	RTC	
•  236	children	with	ADHD	ages	6-17	years	old		
•  8	week	dura5on	
•  Sta5s5cally	significant	results	with	outcome	scales	of	ADHD-RS-
IV,	Conner’s	Parent	Ra5ng	Scale,	Parent	Global	Assessment,	and	
Clinical	Global	Impression	of	Improvement	and	Severity	Scale	
•  Clonidine	ER	saw	a	quick	response	to	treatment	star5ng	at	soon	
as	two	weeks		
u Limita5on:	short	dura5on	and	sample	size,	required	same	dose	
5tra5ons	during	this	8-week	period	(limits	the	individual	
therapeu5c	needs	of	the	pa5ent)	
(Jain,	Segal,	Kollins,	&	Khayrallah,	2011)		
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Literature	Review:		
Clonidine	ER	(Kapvay)		v Double-blind	RCT	comparing	Clonidine	ER,	methtylphenidate,	
or	a	combina:on	of	the	two	medica:ons		
•  122	children	with	ADHD	ages	7-12		
•  16	week	dura:on	
•  Conner's	Teachers	Abbreviated	Symptom	Ques:onnaire:	showed	
no	improvement	in	the	clonidine	ER	monotherapy	group,	but	did	
show	improvement	in	the	combina:on	of	clonidine	ER/
methylphenidate	group		
•  Conner's	Abbreviated	Symptom	Ques:onnaire	for	Parents	and	
Children's	Global	Assessment	Scale:	showed	improvement	in	
ADHD	symptoms	whether	it	was	in	the	Clonidine	ER	
monotherapy	group	or	the	combina:on	group	
•  Clonidine	ER	was	found	to	be	efficacious	for	certain	ADHD	pa:ent	
subtypes	such	as	those	with	co-morbid	behavioral	and/or	
impulsive	disorders		
(Palumbo	et	al.,	2008)		
  
EFFECTIVENESS OF NON-STIMULANTS FOR ADHD                                             50      
 
Literature	Review:		
Clonidine	ER	(Kapvay)	
v Double	blind	RCT	that	used	either	clonidine	ER	or	a	placebo	to	
a	current	s6mulant	treatment	plan	that	was	not	effec6ve	
•  198	children	and	adolescents	enrolled	over	this	8	week	study		
•  Conner	Parent	Ra6ng	Scale,	Clinical	Global	Impression	of	Severity	
and	improvement,	and	Parent	Global	Assessment,	ADHD-RS-IV	
scale	all	found	sta6s6cally	significant	improvements	in	their	
scores	for	the	clonidine	ER	combina6on	group		
•  Star6ng	at	week	5	the	clonidine	ER	combina6on	group	started	to	
show	sta6s6cally	significant	results	which	con6nued	throughout	
the	remainder	of	the	study		
u Limita6on:	exclusion	of	comorbid	disorders	(eliminates	many	of	
the	ADHD	popula6ons	that	have	co-exis6ng	learning	or	
behavioral	disorders),	variability	in	s6mulant	medica6ons,	no	
clonidine	ER	monotherapy	group	
u Strength:		diverse	pa6ent	popula6on	of	males,	females,	children	
and	adolescents		
(Kollins	et	al.,	2011)		
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Literature	Review:		
Guanfacine	ER	(Intuniv)		v Literature	Review	•  Found	guanfacine	ER	to	have	profound	effects	on	execu9ve	
func9oning	in	children	by	improved	a>en9on	spans,	impulse	control,	
planning,	working	memory,	and	distrac9bility		
•  Improvements	in	behaviors	and	motor	control	were	a>ributed	to	
guanfacine’s	effects	on	the	noradrenergic	projec9ons	to	the	basal	
ganglia	and	cerebellum	
	
v Double	blind	RCT	compares	guanfacine	ER/s9mulant	combina9on	
and	placebo/s9mulant	combina9on	
•  461	par9cipants	of	children/adolescents	with	ADHD	aged	6-17		
•  9	week	dura9on	
•  ADHD-RS-IV	scale,	Clinical	Global	Impressions	of	Severity	of	Illness	
and	Improvement	scales	
•  Significant	improvement	in	scores	for	all	assessment	scales	for	the	
guanfacine	ER/s9mulant	group	verses	the	placebo/s9mulant	group		
u Limita9on:	short	dura9on,	requirement	was	for	a	par9al	response	in	
s9mulant	therapy	already	before	entering	the	trial		
	(Wilens	et	al.,	2012)		
(Strange,	2008)		
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Literature	Review:		
Guanfacine	ER	(Intuniv)	
v Double	blind	RCT	with	placebo-control	
•  329	children/adolescents	aged	6	to	17	years	old	with	ADHD	
•  9	week	duraCon	
•  Guanfacine	ER	was	divided	into	3	separate	dosage	groups		
•  Improvements	in	ADHD-RS-IV	was	reported	for	all	three	
guanfacine	ER	dosage	groups	showing	a	reducCon	in	score	of	
19.6,	compared	to	the	placebo	which	had	a	reducCon	of	12.2		
u LimitaCons:	short	9	week	trial	duraCon	and	a	small	number	of	
adolescents	compared	to	children		
u Strength:	Strict	inclusion	and	exclusion	criteria		
(Sallee	et	al.,	2009)		
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Literature	Review:		
Guanfacine	ER	(Intuniv)	
v Double	blind	RCT	with	placebo-control	
•  345	children/adolescents	aged	6-17	years	old	with	ADHD	
•  8	week	duraDon	
•  3	different	guanfacine	ER	dosage	groups	
•  Average	change	in	ADHD-RS-IV	scores	for	the	guanfacine	ER	
groups	were	17.16	and	the	placebo	group	was	8.48		
•  Secondary	efficacy	scales	of	Clinical	Global	Impression	of	
Improvement,	Parent's	Global	Assessment,	Conners’	Parent	and	
Teacher	RaDng	Scale–Revised,	and	Conners’	Teacher	RaDng	
Scale–revised	found	significant	improvements	in	the	guanfacine	
ER	groups		
u LimitaDons:	short	duraDon	
(Biederman	et	al.,	2008)		
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Literature	Review:		
Guanfacine	ER	(Intuniv)	
v Literature	review	
•  Guanfacine	ER	was	found	to	be	favorable	for	pediatric	pa7ents	
with	ADHD	that	had	dominant	opposi7onal	symptoms		
•  Found	varying	results	in	the	efficacy	onset	of	guanfacine	ER,	
ranging	from	1-4	weeks		
•  Combina7on	therapy	with	a	s7mulant	was	found	to	be	beneficial	
in	children	who	were	not	experiencing	the	full	treatment	
poten7al	of	s7mulant	medica7ons		
•  ADHD-RS-IV	scores	saw	improvements	with	guanfacine	ER/
s7mulant	combina7on	therapy	in	children	with	opposi7on	
symptoms	and	those	without		
(Faraone,	McBurneP,	Sallee,	Steeber,	&	López,	2013;	Childress	&	Berry,	2012)	
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Results	
•  Fi#een	ar)cles	included	nine	RCTs,	three	literature	reviews,	
one	non-randomized	study,	one	meta-analysis,	and	one	
systemic	review		
•  RCT	studies	were	found	to	be	very	beneficial	because	there	
was	elabora)on	on	the	specific	types	of	outcome	
measurement	tools	that	were	u)lized		
•  Most	common	scale	that	was	used	was	the	ADHD-RS-IV-
Parent	and	the	Clinical	Global	Impression	and	Severity	Scale		
•  Most	of	these	scales	had	either	a	parent/guardian	or	teacher	
comple)ng	the	scale	
•  The	non-randomized	study	did	not	use	a	scale;	the	Stroop	
Word-Color	Test	and	NIRS	score	was	performed	instead		
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Results		
v Six	ar'cles	studied	the	effec'veness	of	atomoxe'ne:	
§  All	6	ar'cles	agreed	atomoxe'ne	was	an	effec've	medica'on	for	
the	treatment	of	ADHD	in	the	pediatric	popula'on	with	
sta's'cally	significant	results	
§  Two	ar'cles	found	atomoxe'ne	to	have	more	rapid	onset	than	
the	placebo	
§  One	study	found	the	NIRS	exam	to	have	increased	prefrontal	
cortex	ac'vity	especially	in	the	leF	lateral	frontal	lobe	when	on	
atomoxe'ne		
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Results	
v Four	ar'cles	studied	the	effec'veness	of	clonidine	ER:	
•  All	4	ar'cles	agreed	clonidine	ER	was	an	effec've	medica'on	for	
the	treatment	of	ADHD	in	the	pediatric	popula'on	with	
sta's'cally	significant	results	
•  Two	out	of	the	three	RCT’s	compared	the	effec'veness	of	
clonidine	ER	as	an	adjunct	medica'on	to	s'mulant	treatment	
•  One	systemic	review	highly	supported	its	use	as	an	adjunct	
medica'on	to	s'mulant	therapy	and	found	clonidine	ER	to	be	
more	helpful	with	behavioral	symptoms		
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Results	
v Five	ar(cles	studied	the	effec(veness	of	guanfacine	ER:		
•  All	5	ar(cles	agreed	guanfacine	ER	was	an	effec(ve	medica(on	
for	the	treatment	of	ADHD	in	the	pediatric	popula(on	with	
sta(s(cally	significant	results	
•  Three	ar(cles	found	guanfacine	ER	to	be		an	effec(ve	adjunct	to	
s(mulant	treatment	
•  One	ar(cle	found	guanfacine	ER	to	be	specifically	efficacious	in	
children	with	opposi(onal	symptoms		
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Implications	in…	
Nursing	Prac,ce	
•  Choosing	to	prescribe	non-
s0mulants	over	the	best	
prac0ce	guideline	of	s0mulants,	
can	demonstrate	how	the	APPN	
is	providing	holis0c	care	by	
addressed	all	aspects	of	the	
pa0ents	needs	and	concerns		
•  Con0nue	to	further	one’s	
educate	is	very	important	
because	new	evidence-based	
research	becomes	published	
and	knowledge	behind	
understanding	the	brain	and	
how	it	relates	to	ADHD	is	
increasing	
Research		
•  Limited	research	on	non-
s0mulant	monotherapy;	many	
ar0cles	were	evalua0ng	
s0mulant	therapy	and/or	
s0mulant	with	adjunct	non-
s0mulant	therapy		
•  More	research	is	needed	to	
determine	what	outcome	
measurement	scale	is	best	to	
determine	effec0veness	of	a	
medica0on,	studies	with	longer	
dura0on,	greater	sample	size,	
and	with	a	focused	
monotherapy	experimental	
group	to	strength	the	validity	of	
their	findings		
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Implications	in…	
Educa&on		
•  It	is	important	for	the	
APPN	to	be	educated	on	
medica6ons,	including	
their	evidence-based	
research,	to	guide	
treatment	decisions	and		to	
provide	pyschoeduca6on	
to	their	pa6ents		
						(American	Nurses	Associa6on,	2014)		
•  With	knowledge	of	the	
evidence-based	research,	
the	APPN	can	educate	the	
pa6ent	and	their	parents/
guardians	regarding	its	
effec6veness	and	how	the	
medica6on	will	target	the	
core	symptoms	of	ADHD		
Health	Policy	
•  Policies	at	hospitals,	
outpa6ent	seJngs,	and	
state	levels	can	be	
impacted	by	the	results	of	
this	literature	review	by	
APPN’s	advoca6ng	for	
updated	policies	for	
treatment	op6ons		
•  APPN	can	support	
con6nuing	research	by	
having	their	pa6ent	enroll	
in	research	studies		
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Conclusion	
•  ADHD	is	a	complex	disorder	with	the	poten5al	to	leave	
profound	effects	on	one’s	childhood	and	development	when	
not	treated	effec5vely		
•  Atomoxe5ne,	clonidine	ER,	and	guanfacine	ER	were	found	to	
have	sta5s5cally	significant	results	despite	the	use	of	differing	
yet	similar	outcome	measurement	scales		
•  Con5nuing	research	is	needed	to	maintain	these	medica5ons	
as	treatment	op5ons	for	this	popula5on		
	
With	the	results	of	this	literature	review,	the	APPN	can	make	
evidence-based	decisions	during	treatment	planning	for	their	
pediatric	pa=ent	with	ADHD		
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